A Novel Theranostic Strategy for MMP-14–Expressing Glioblastomas Impacts Survival
- Submitting institution
-
The University of Bradford
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- 161
- Type
- D - Journal article
- DOI
-
10.1158/1535-7163.MCT-17-0022
- Title of journal
- Molecular Cancer Therapeutics
- Article number
- -
- First page
- 1909
- Volume
- 16
- Issue
- 9
- ISSN
- 1535-7163
- Open access status
- Compliant
- Month of publication
- -
- Year of publication
- 2017
- URL
-
https://mct.aacrjournals.org/content/16/9/1909
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
15
- Research group(s)
-
-
- Citation count
- 18
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- This is an international multi-disciplinary output with contributions in complementary areas, including medicinal chemistry, nanoparticle characterisation, in vitro/in vivo biology, and MRI imaging. RAF provided direct input into the concept underpinning the study, experimental design, co-supervised the study, and played a significant role in writing, editing and revising the final manuscript, with key intellectual contributions in the areas of MMP cancer prodrug activation, vascular-disrupting agents, and combination treatments. The medicinal chemistry was led by RAF at Bradford, who directly contributed the synthesis and analysis of the peptide prodrug used in this study. CLIO-ICT is a joint Stanford-Bradford invention (patent: Daldrup-Link/RAF/PML).
- Non-English
- No
- English abstract
- -
